2018 Archived Content
OVERVIEW | DOWNLOAD BROCHURE | SPEAKERS | ATTENDEE LIST | SHORT COURSES

21 May 2018
14:00-17:00

Liquid Biopsy for P4 Medicine: Predictive, Preventive, Personalized and Participatory

Instructors

Clotilde Costa Nogueira, Ph.D., Head, Liquid Biopsy Line, Roche-Chus Joint Unit, University Hospital of Santiago de Compostela, Spain

Lorena Diéguez, Ph.D., Staff Researcher, Diagnostic Tools and Methods Research Group, Life Sciences, International Iberian Nanotechnology Laboratory, Portugal


P4 Medicine is Predictive, Preventive, Personalized and Participatory. The P4 medicine concept is fully realised in the context of Liquid Biopsy, since patient’s blood is used as a biomarker for the prognosis and diagnosis of the disease status. Therefore, Liquid Biopsy provides the ideal scheme to personalize the treatment in precision medicine. P4 medicine will permit to identify predictive and preventive biomarkers and genomic mapping, adapting treatments to each patient, and having the patients engaged for a successful outcome.

Course Outline:

  • Introduction
  • Biomarkers in liquid biopsy: CTCs, ctDNA and exosomes
  • Advances in enabling technology for liquid biopsy
  • Clinical applications
  • Sampling
  • Round table: Why must Liquid Biopsy be P4?
  • Concluding remarks

Instructor Biographies

Clotilde_CostaClotilde Costa Nogueira, Ph.D., Head, Liquid Biopsy Line, Roche-Chus Joint Unit, University Hospital of Santiago de Compostela, Spain

Dr. Costa obtained Biology degree from the University of Vigo (Spain). During her phD thesis period (2006-2011), in the Molecular Oncology Unit in the CIEMAT /UAM (Madrid, Spain), she study the role of different cell cycle genes (Rb1, Rbl1, E2F1, E2F4) in the epidermal carcinogenesis development. Her work revealed the existence of unknown molecular pathways responsible for carcinogenesis not previously described. In 2013 she joined the Translational medical oncology group, located in the Clinical Hospital of Santiago de Compostela to work in the field of Liquid Biopsy. In 2015 she moved to the Roche-Chus Joint Unit for precision oncology (within the Translational Medical Oncology Group) as leader of the Liquid Biopsy laboratory, focus on characterization of CTCs and identification of biomarkers for therapy resistance in Breast and Prostate metastatic cancer patients.

Lorena_DieguezLorena Diéguez, Ph.D., Staff Researcher, Diagnostic Tools and Methods Research Group, Life Sciences, International Iberian Nanotechnology Laboratory, Portugal

Lorena Diéguez is since 2014 the head of the Biomicrofluidic Devices group at the International Iberian Nanotechnology Laboratory (INL), devoted to Translational Medical Research in close collaboration with Hospitals. Her research activities are currently focused on the development of nanobioengineered microsystems for the isolation and characterization of Tumor Cells from body fluids of cancer patients. She obtained her Bachelor’s degree in Physics and her Masters in Optoelectronics at the University of Santiago de Compostela, then completed her Masters in Nanoscience and Nanotechnology at the University of Barcelona (UB) and obtained her PhD in Nanosciences in optical and electrochemical biosensors at the Institute for Bioengineering of Catalonia and the ETH Zürich. Her postdoctoral research at the University of South Australia (UniSA) was devoted to the study of rare cells from biological samples using microfluidics.